Myriad Genetics Inc
NASDAQ:MYGN
Myriad Genetics Inc
NASDAQ:MYGN
Price:
22.955 USD
2.2%
Market Closed
Updated:
Jun 1, 2024
Myriad Genetics Inc
Total Equity
|
Myriad Genetics Inc
Total Equity Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Myriad Genetics Inc
NASDAQ:MYGN
|
Total Equity
$760m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is Myriad Genetics Inc's Total Equity?
Total Equity
760m
USD
760m
USD
Based on the financial report for Mar 31, 2024, Myriad Genetics Inc's Total Equity amounts to 760m USD.
What is Myriad Genetics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
1%
1%
Over the last year, the Total Equity growth was -9%. The average annual Total Equity growth rates for Myriad Genetics Inc have been -5% over the past three years , -7% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
